An open letter to Congress: Stand with patients and future cures
I recently joined PhRMA board members in penning the letter below to Congress, urging them to abandon their latest drug pricing proposal. You can read […]
I recently joined PhRMA board members in penning the letter below to Congress, urging them to abandon their latest drug pricing proposal. You can read […]
PhRMA member companies’ continued investment in research and development (R&D) has led to new medicines transforming human health. Innovative biopharmaceutical approaches to treating patients for […]
Today, researchers from PhRMA member companies will meet virtually with members of Congress and Capitol Hill staff to discuss the importance of biopharmaceutical innovation in […]
Our industry continues working to build a more resilient, affordable and equitable health care system. As part of Mental Health Awareness Month, I recently had […]
The innovative biopharmaceutical industry has long been a significant driver of the nation’s economic growth and a key contributor to state and regional economies. A […]
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The […]
I am excited to join with Dr. Michael L. Lomax, President & CEO, UNCF; Dr. James Gillespie, President & Co-Founder, Center for Healthcare Innovation (CHI); […]
Our industry has committed itself to making our workplaces trusting places to have complex, and sometimes difficult, conversations about diversity and inclusion.
This month, PhRMA hosted a media briefing with leaders within the biopharmaceutical industry to discuss the dangers of current proposals on government price setting, while also sharing alternative solutions that […]
PhRMA member companies’ robust investment in research and development (R&D) has led to advances and discoveries that are transforming health care and our approach to […]
On June 22, during The Atlantic’s Health Equity Summit, PhRMA hosted a conversation on clinical trial diversity. PhRMA Chief Operating Officer Lori Reilly and Genentech […]
Our industry continues to work tirelessly to combat the COVID-19 virus by developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. As […]
Today, biopharmaceutical researchers from PhRMA member companies are meeting virtually with members of Congress and staff to share their stories of transforming game-changing scientific discoveries into […]
Last week, PhRMA submitted comments to the United States Patent and Trademark Office (USPTO) in response to a request for comments on the National Strategy […]
This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to […]
Our industry has committed itself to making our workplaces trusting places to have complex, and sometimes difficult, conversations about diversity and inclusion.
Today, PhRMA released a new report prepared by TEConomy Partners, LLC that provides insights into the efforts of biopharmaceutical companies to advance diversity & inclusion […]
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The […]
This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to […]
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in […]
This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to […]
Biopharmaceutical researchers are at the heart of a robust American research and development (R&D) ecosystem that develops more innovative medicines than any other country in […]
Over the last seven months, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 […]
Over the last seven months, our industry has been working around the clock to combat the COVID-19 virus, including developing potential therapeutics to treat COVID-19 […]
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The […]
PhRMA member companies invested $83 billion in research and development (R&D) in 2019, the highest level of investment on record, according to the 2020 PhRMA […]
America’s biopharmaceutical companies are working around the clock to defeat COVID-19, a disease caused by a novel strain of the coronavirus. The biopharmaceutical industry continues […]
Conversations and healthy debate about issues facing the biopharmaceutical industry and the health care system are critical to addressing the important work we do for […]
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The […]
America’s biopharmaceutical companies are working around the clock to combat a common enemy: COVID-19. As the fight to research and develop innovative treatments and vaccines […]
Copyright © 2024 | WordPress Theme by MH Themes